Several cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease are available, including total tau and phosphorylated tau protein, reflecting neurodegeneration and tau pathology, respectively, and amyloid-β1–42 reflecting deposition of the peptide into plaques [2, 3]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.